Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENPULIMAB-KCQX vs PORTRAZZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Penpulimab-kcqx is a humanized monoclonal antibody that binds to programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
Unresectable or metastatic hepatocellular carcinoma (HCC) in patients who have not received prior systemic therapy
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.
200 mg intravenously over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
Terminal elimination half-life is approximately 22 days (range: 15–27 days) in patients receiving 2 mg/kg or 200 mg every 3 weeks. This long half-life supports every-3-week dosing. Clearance decreases over time due to target-mediated drug disposition and saturable binding to PD-1 receptors.
Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade.
Penpulimab-kcqx is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via general protein catabolism.
Metabolism of necitumumab has not been fully characterized. As a monoclonal antibody, it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways.
Pembrolizumab is a humanized monoclonal antibody (Ig G4) that undergoes catabolism via the reticuloendothelial system (RES) to small peptides and amino acids; no renal or biliary excretion of intact antibody occurs. Elimination pathways (%): catabolism (100%), unchanged renal excretion (<1%), unchanged biliary/fecal excretion (<1%).
Necitumumab is an Ig G1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established.
Pembrolizumab is not bound to plasma proteins (0% protein binding). As a monoclonal antibody, it circulates freely in plasma.
Necitumumab is a monoclonal antibody; target-mediated binding to EGFR occurs, but nonspecific plasma protein binding is negligible. No specific protein binding percentage is reported.
Vd is approximately 0.06 L/kg (range: 0.04–0.08 L/kg) in adults, indicating limited extravascular distribution consistent with a large Ig G antibody that remains primarily in the intravascular space (about 6 L in a 70 kg adult).
Volume of distribution at steady state is approximately 5.8 L (range 4.7–7.1 L), suggesting distribution primarily in the vascular space and minimal extravascular distribution.
Pembrolizumab is administered only intravenously; bioavailability is 100% by IV route. No oral or subcutaneous formulation is approved. Subcutaneous bioavailability is not determined.
Intravenous: 100% (not applicable to other routes).
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment is recommended for patients with mild to moderate renal impairment. There is no data for severe renal impairment (Cr CL <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended in moderate or severe hepatic impairment (Child-Pugh B or C) due to lack of data.
No formal studies have been conducted in patients with hepatic impairment. No dose adjustment is recommended for mild hepatic impairment (Child-Pugh A). Use caution in moderate to severe hepatic impairment due to lack of data.
Safety and efficacy not established in pediatric patients. No recommended dose.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment required; geriatric patients in clinical studies received the same dose as younger adults. Monitor for increased adverse reactions.
No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed compared to younger patients.
None
No black box warnings.
Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions,Infusion-related reactions,Embryo-fetal toxicity
Cardiopulmonary arrest and/or sudden death occurred in 3% of patients receiving necitumumab in combination with gemcitabine and cisplatin; monitor electrolytes and consider withholding for severe electrolyte abnormalities.,Arterial thromboembolic events (ATEs) occurred in 5% of patients; permanently discontinue for serious ATEs.,Venous thromboembolic events (VTEs) including pulmonary embolism occurred; permanently discontinue for life-threatening VTEs.,Hemolytic-uremic syndrome (HUS) reported; discontinue if HUS is suspected.,Dermatologic toxicities including rash, dry skin, and pruritus; monitor and manage accordingly.,Infusion-related reactions; interrupt or discontinue for severe reactions.,Hypomagnesemia occurred in 83% of patients; monitor magnesium, calcium, and potassium prior to each dose.,Embryofetal toxicity: can cause fetal harm; advise females of reproductive potential of effective contraception.
None
No known contraindications from the manufacturer.
No known food interactions. Avoid grapefruit juice if co-administered with CYP3A4 substrates. Maintain adequate hydration.
No specific food interactions have been identified with necitumumab. However, maintain adequate hydration and nutrition. Grapefruit and other CYP3A4 inhibitors are not expected to interact since necitumumab is a monoclonal antibody cleared via proteolysis.
PENPULIMAB-KCQX is a human Ig G4 monoclonal antibody. Ig G molecules are actively transported across the placenta during the third trimester. Based on its mechanism of action (PD-1 blockade), there is a potential risk of immune-mediated fetal harm including increased rates of abortion, stillbirth, and neonatal death, as observed in animal models. Human data are limited. Use during pregnancy should be avoided unless the potential benefit outweighs the risk. There is no known risk specifically by trimester, but the greatest transfer occurs after 30 weeks gestation.
Portrazza (necitumumab) is an Ig G1 monoclonal antibody. Ig G molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to therapeutic concentrations. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (EGFR inhibition), there is a risk of fetal harm, including developmental abnormalities and fetal loss. Women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose.
It is unknown whether PENPULIMAB-KCQX is excreted in human milk. Human Ig G is present in breast milk, but the amount and potential for systemic absorption in the infant are low. Due to the potential for adverse reactions in the nursing infant, breastfeeding is not recommended during treatment and for at least 5 half-lives (approximately 150 days) after the last dose. No M/P ratio is available.
It is not known whether necitumumab is excreted in human milk. Human Ig G is known to be present in milk, but the amount is generally low. Due to the potential for serious adverse reactions in nursing infants, advise women not to breast-feed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
No specific dosing adjustment guidelines exist for pregnancy. Pregnancy may alter pharmacokinetics of monoclonal antibodies due to increased plasma volume and altered clearance, but data are insufficient to recommend dose changes. Use the standard adult dose if treatment is deemed necessary. However, due to potential fetal harm, avoid use during pregnancy unless clearly needed.
No specific dosing adjustments for pregnancy are established. However, physiological changes during pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics. Currently, no dose modification is recommended due to lack of data; however, caution is advised, and treatment should only be used if the potential benefit justifies the potential risk to the fetus.
Administer intravenous infusion over 30 minutes. Premedicate with antihistamines and antipyretics to reduce infusion-related reactions. Monitor for immune-related adverse effects, particularly pneumonitis, colitis, hepatitis, and endocrinopathies. Do not mix with other drugs in the same infusion line. Use 5% dextrose in water or 0.9% sodium chloride for dilution.
PORTRAZZA (necitumumab) is a human Ig G1 monoclonal antibody targeting EGFR. Prior to initiation, confirm EGFR expression in squamous non-small cell lung cancer. Premedicate with H1 antagonists to reduce infusion-related reactions. Monitor for hypomagnesemia, which can occur weeks after treatment; replete as needed. Avoid use in patients with a history of severe infusion reactions to other EGFR inhibitors.
Report any new or worsening cough, chest pain, or shortness of breath immediately.,Notify your healthcare provider if you experience diarrhea, abdominal pain, or blood in stool.,Watch for signs of hepatitis: yellowing of skin or eyes, dark urine, severe nausea or vomiting, or bleeding/bruising.,Inform your doctor if you develop severe fatigue, weight gain or loss, hair thinning, depression, or changes in heart rate.,Use effective contraception during treatment and for at least 4 months after the last dose.
Inform your doctor if you experience severe skin rash, diarrhea, or infusion reactions during treatment.,Report any signs of low magnesium such as muscle cramps, numbness, or irregular heartbeat.,Avoid sun exposure and use broad-spectrum sunscreen SPF 50+; this drug increases photosensitivity.,Do not receive live vaccines while on PORTRAZZA.,Use effective contraception during treatment and for 3 months after the last dose if you are of childbearing potential.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENPULIMAB-KCQX vs PORTRAZZA, answered by our medical review team.
PENPULIMAB-KCQX is a Antineoplastic Monoclonal Antibody that works by Penpulimab-kcqx is a humanized monoclonal antibody that binds to programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.. PORTRAZZA is a Antineoplastic Monoclonal Antibody that works by PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENPULIMAB-KCQX and PORTRAZZA depend on the specific clinical indication. These are both Antineoplastic Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENPULIMAB-KCQX is: 200 mg intravenously over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of PORTRAZZA is: PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENPULIMAB-KCQX and PORTRAZZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENPULIMAB-KCQX is classified as Category C. PENPULIMAB-KCQX is a human IgG4 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester. Based on its mechanism of action (PD-1 b. PORTRAZZA is classified as Category C. Portrazza (necitumumab) is an IgG1 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to the. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.